Search results for: Anti-ZMAT3 Antibody
#38639818 
2024/04/19
To Up
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
The paper extended the TMDD model to drugs with more than two (N > 2) identical binding sites (N-to-one TMDD). The quasi-steady-state (N-to-one QSS), quasi-equilibrium (N-to-one QE), irreversible binding (N-to-one IB), and Michaelis-Menten (N-to-one MM) approximations of the model were derived. To illustrate properties of new equations and approximations, N = 4 case was investigated numerically. Using simulations, the N-to-one QSS approximation was compared with the full N-to-one TMDD model. As expected, and similarly to the standard TMDD for monoclonal antibodies (mAb), N-to-one QSS predictions were nearly identical to N-to-one TMDD predictions, except for times of fast changes following initiation of dosing, when equilibrium has not yet been reached. Predictions for mAbs with soluble targets (slow elimination of the complex) were simulated from the full 4-to-one TMDD model and were fitted to the 4-to-one TMDD model and to its QSS approximation. It was demonstrated that the 4-to-one QSS model provided nearly identical description of not only the observed (simulated) total drug and total target concentrations, but also unobserved concentrations of the free drug, free target, and drug-target complexes. For mAb with a membrane-bound target, the 4-to-one MM approximation adequately described the data. The 4-to-one QSS approximation converged 8 times faster than the full 4-to-one TMDD.Leonid Gibiansky, Chee M Ng, Ekaterina Gibiansky
1568 related Products with: Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.
100 ul250ul100 ul100 ul250ul25 Tests200 100.00 ug100 ml 100ul1000 TESTS/0.65ml
Related Pathways
#38639795 2024/04/19
To Up
Gn protein expressed in plants for diagnosis of severe fever with thrombocytopenia syndrome virus.
SYu-Chih Chang, Hiroshi Shimoda, Min-Chao Jiang, Yau-Heiu Hsu, Ken Maeda, Yumiko Yamada, Wei-Li Hsu
2348 related Products with: Gn protein expressed in plants for diagnosis of severe fever with thrombocytopenia syndrome virus.
1 Set100100 1001 Set1 mL1 Set1 Set1 Set10ìg1 Set100
Related Pathways
-
No related Items
#38639788 2024/04/19
To Up
Teprotumumab improves light sensitivity in patients with thyroid eye disease.
Teprotumumab, a novel IGF-1R antibody, has been shown to significantly reduce the signs of acute and chronic Thyroid Eye Disease (TED). Light sensitivity is a reported symptom in patients with TED. There is a lack of a prospective study that has explored the effects on light sensitivity in a large cohort of patients with acute and chronic TED following treatment with teprotumumab.Emanuil Parunakian, Shoaib Ugradar, Joseph Tolentino, Emil Malkhasyan, Pershanjit Raika, Joseph Ghaly, Chirag Bisht, Raymond S Douglas
1161 related Products with: Teprotumumab improves light sensitivity in patients with thyroid eye disease.
1 mg96 wells (1 kit)
Related Pathways
#38639726 2024/04/19
To Up
Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System.
Effective antitumor immunotherapy depends on evoking a cascade of cancer-immune cycles with lymph nodes (LNs) as the initial sites for activating antitumor immunity, making drug administration through the lymphatic system highly attractive. Here, we describe a nanomedicine with dual responsiveness to pH and enzyme for a programmed activation of antitumor immune through the lymphatic system. The proposed nanomedicine can release the STING agonist diABZI-C2-NH in the LNs' acidic environment to activate dendritic cells (DCs) and T cells. Then, the remaining nanomedicine hitchhikes on the activated T cells (PD-1 T cells) through binding to PD-1, resulting in an effective delivery into tumor tissues owing to the tumor-homing capacity of PD-1 T cells. The enzyme matrix metalloproteinase-2 (MMP-2) being enriched in tumor tissue triggers the release of PD-1 antibody (aPD-1) which exerts immune checkpoint blockade (ICB) therapy. Eventually, the nanomedicine delivers a DNA methylation inhibitor GSK-3484862 (GSK) into tumor cells, and then the latter combines with granzyme B (GZMB) to trigger tumor cell pyroptosis. Consequently, the pyroptotic tumor cells induce robust immunogenic cell death (ICD) enhancing the DCs maturation and initiating the cascading antitumor immune response. Study on a 4T1 breast tumor mouse model demonstrates the prominent antitumor therapeutic outcome of this nanomedicine through creating a positive feedback loop of cancer-immunity cycles including immune activation in LNs, T cell-mediated drug delivery, ICB therapy, and tumor cell pyroptosis-featured ICD.Hong Xiao, Xiaoxia Li, Simin Liang, Shuguang Yang, Shisong Han, Jinsheng Huang, Xintao Shuai, Jie Ren
1272 related Products with: Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System.
70 Slides 500 Slides 10, 10ml whole blood 70 Slides 1 kit(s) 1 system 70 Slides
Related Pathways
#38639536 2024/04/19
To Up
A panel of recombinant cell surface and secreted proteins identifies LdBPK_323600.1 as a serological marker of symptomatic infection.
Visceral leishmaniasis is a deadly infectious disease and is one of the world's major neglected health problems. Because the symptoms of infection are similar to other endemic diseases, accurate diagnosis is crucial for appropriate treatment. Definitive diagnosis using splenic or bone marrow aspirates is highly invasive, and so, serological assays are preferred, including the direct agglutination test (DAT) or rK39 strip test. These tests, however, are either difficult to perform in the field (DAT) or lack specificity in some endemic regions (rK39), making the development of new tests a research priority. The availability of spp. genomes presents an opportunity to identify new diagnostic targets. Here, we use genome data and a mammalian protein expression system to create a panel of 93 proteins consisting of the extracellular ectodomains of the cell surface and secreted proteins. We use these panel and sera from murine experimental infection models and natural human and canine infections to identify new candidates for serological diagnosis. We observed a concordance between the most immunoreactive antigens in different host species and transmission settings. The antigen encoded by the gene can diagnose infections with high sensitivity and specificity in patient cohorts from different endemic regions including Bangladesh and Ethiopia. In longitudinal sampling of treated patients, we observed reductions in immunoreactivity to LdBPK_323600.1 suggesting it could be used to diagnose treatment success. In summary, we have identified new antigens that could contribute to improved serological diagnostic tests to help control the impact of this deadly tropical infectious disease.Adam J Roberts, Han Boon Ong, Simon Clare, Cordelia Brandt, Katherine Harcourt, Yegnasew Takele, Prakash Ghosh, Angela Toepp, Max Waugh, Daniel Matano, Anna Färnert, Emily Adams, Javier Moreno, Margaret Mbuchi, Christine Petersen, Dinesh Mondal, Pascale Kropf, Gavin J Wright
1989 related Products with: A panel of recombinant cell surface and secreted proteins identifies LdBPK_323600.1 as a serological marker of symptomatic infection.
100ul1mg2100mg100tests102010000
Related Pathways
#38639534 //
To Up
The safety signal detection and analysis of monoclonal antibodies against SARS-CoV-2 based on real-world evidence - the suitable selectivity for different populations.
Bebtelovimab (BEB), Tixagevimab/Cilgavimab (TIX/CIL), and Sotrovimab (SOT) are important agents against the severe acute respiratory syndrome coronavirus 2-Omicron strain. However, due to their short duration of application, little is known about their safety profiles. This research aimed to explore the safety profile of these monoclonal antibodies (mAbs) via real-world evidence databases and data mining tools.Y Wang, X-W Xu, S Zhou, J-N Li
2790 related Products with: The safety signal detection and analysis of monoclonal antibodies against SARS-CoV-2 based on real-world evidence - the suitable selectivity for different populations.
1 ml1 ml100ug/vial200ug100ug/vial10.1 mg100 ug2000 IU
Related Pathways
-
No related Items
#38639426 2024/04/19
To Up
Comparative analysis of tropomyosin allergenicity in three different species of molluscs: insights into the role of amino acid composition in IgE epitopes.
Limited research has been conducted on the differences in allergenicity among tropomyosin (ATM), tropomyosin (HTM), and tropomyosin (MTM) in molluscs. Our study aimed to comprehensively analyze and compare their immunoreactivity, sensitization, and allergenicity while simultaneously elucidating the underlying molecular mechanisms involved. We assessed the immune binding activity of TM utilizing 86 sera from allergic patients and evaluated sensitization and allergenicity through two different types of mouse models. The dot-blot and basophil activation test assays revealed strong immunoreactivity for HTM, ATM, and MTM, with HTM exhibiting significantly lower levels compared to ATM. In the BALB/c mouse sensitization model, all TM groups stimulated the production of specific antibodies, elicited IgE-mediated immediate hypersensitivity responses, and caused an imbalance in the IL-4/IFN-γ ratio. Similarly, in the BALB/c mouse model of food allergy, all TM variants induced IgE-mediated type I hypersensitivity responses, leading to the development of food allergies characterized by clinical symptoms and an imbalance in the IL-4/IFN-γ ratio. The stimulation ability of sensitization and the severity of food allergies consistently ranked as ATM > MTM > HTM. Through an in-depth analysis of non-polar amino acid frequency and polar hydrogen bonds, HTM exhibited higher frequencies of non-polar amino acids in its amino acid sequence and IgE epitopes, in comparison with ATM and MTM. Furthermore, HTM demonstrated a lower number of polar hydrogen bonds in IgE epitopes. Overall, HTM exhibited the lowest allergenic potential in both allergic patients and mouse models, likely due to its lower polarity in the amino acid sequence and IgE epitopes.Xinyu Han, Xinrong He, Xinya Wang, Lianzhong Luo, Yubao Li, Dong Lai, Hong Liu, Jingwen Liu, Shitao Rao, Guangming Liu
2490 related Products with: Comparative analysis of tropomyosin allergenicity in three different species of molluscs: insights into the role of amino acid composition in IgE epitopes.
100ug50 ug 100ug1 g0.5 mg 100ul1 g5 mg 100ul 1 G100ug Lyophilized10 ug
Related Pathways
#38639407 2024/04/19
To Up
Dynamic Hybrid Module-Driven NK Cell Stimulation and Release for Tumor Immunotherapy.
Natural killer (NK) cells have become a powerful candidate for adoptive tumor immunotherapy, while their therapeutic efficacy in solid tumors remains unsatisfactory. Here, we developed a hybrid module with an injectable hydrogel and hydroxyapatite (HAp) nanobelts for the controlled delivery of NK cells to enhance the therapy of solid tumors. Surface-functionalized HAp nanobelts modified with agonistic antibodies against NKG2D and 4-1BB and cytokines IL-2 and IL-21 support survival and dynamic activation. Thus, the HAp-modified chitosan (CS) thermos-sensitive hydrogel not only improved the retention of NK cells for more than 20 days but also increased NK cell function by more than one-fold. The unique architecture of this biomaterial complex protects NK cells from the hostile tumor environment and improves antitumor efficacy. The generation of a transient inflammatory niche for NK cells through a biocompatible hydrogel reservoir may be a conversion pathway to prevent cancer recurrence of resectable tumors.Deyan Jiao, Min Hao, Renhui Sun, Xiaolei Ren, Yanfei Wei, Miaomiao Ding, Xuetian Yue, Zhuanchang Wu, Chunyang Li, Lifen Gao, Chunhong Ma, Yuanhua Sang, Xiaohong Liang, Hong Liu
1155 related Products with: Dynamic Hybrid Module-Driven NK Cell Stimulation and Release for Tumor Immunotherapy.
500 ml10 lt50 ml10 ml1mg50 ml
Related Pathways
#38639400 2024/04/19
To Up
AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.
A traceless site-selective conjugation method, "AJICAP-M", was developed for native antibodies at sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios, enhanced stability, and simplified manufacturing. Comparative in vivo assessment demonstrated AJICAP-M's superior stability over traditional ADCs. This technology has been successfully applied to continuous-flow manufacturing, marking the first achievement in site-selective ADC production. This manuscript outlines AJICAP-M's methodology and its effectiveness in ADC production.Yutaka Matsuda, Natsuki Shikida, Noriko Hatada, Kei Yamada, Takuya Seki, Yuichi Nakahara, Yuta Endo, Kazutaka Shimbo, Kazutoshi Takahashi, Akira Nakayama, Brian A Mendelsohn, Tomohiro Fujii, Tatsuya Okuzumi, Shigeo Hirasawa
2387 related Products with: AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.
100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug Lyophilized100μg100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized0.1mg100ug Lyophilized
Related Pathways
#38639399 2024/04/19
To Up
H3K4me3-Mediated FOXJ2/SLAMF8 Axis Aggravates Thrombosis and Inflammation in β2GPI/Anti-β2GPI-Treated Monocytes.
Antiphospholipid syndrome (APS) is characterized by thrombus formation, poor pregnancy outcomes, and a proinflammatory response. H3K4me3-related monocytes activation are key regulators of APS pathogenesis. Therefore, H3K4me3 CUT&Tag and ATAC-seq are performed to examine the epigenetic profiles. The results indicate that the H3K4me3 signal and chromatin accessibility at the FOXJ2 promoter are enhanced in an in vitro monocyte model by stimulation with β2GPI/anti-β2GPI, which mimics APS, and decreases after OICR-9429 administration. Furthermore, FOXJ2 is highly expressed in patients with primary APS (PAPS) and is the highest in patients with triple-positive antiphospholipid antibodies (aPLs). Mechanistically, FOXJ2 directly binds to the SLAMF8 promoter and activates SLAMF8 transcription. SLAMF8 further interacts with TREM1 to stimulate TLR4/NF-κB signaling and prohibit autophagy. Knockdown of FOXJ2, SLAMF8, or TREM1 blocks TLR4/NF-κB and provokes autophagy, subsequently inhibiting the release of inflammatory and thrombotic indicators. A mouse model of vascular APS is established via β2GPI intraperitoneal injection, and the results suggest that OICR-9429 administration attenuates the inflammatory response and thrombus formation by inactivating FOXJ2/SLAMF8/TREM1 signaling. These findings highlight the overexpression of H3K4me3-mediated FOXJ2 in APS, which consequently accelerates APS pathogenesis by triggering inflammation and thrombosis via boosting the SLAMF8/TREM1 axis. Therefore, OICR-9429 is a promising candidate drug for APS therapy.Yuan Tan, Jiao Qiao, Shuo Yang, Hongchao Liu, Qingchen Wang, Qi Liu, Weimin Feng, Liyan Cui